E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for Advanced Influenza Technologies, Inc. > News item
Published on 7/21/2006 in the Prospect News Biotech Daily.

CytoDyn acquires Advanced Influenza Technologies from UTEK Corp.

By E. Janene Geiss

Philadelphia, July 21 - CytoDyn, Inc. and UTEK Corp. announced Friday that CytoDyn has acquired Advanced Influenza Technologies, Inc., a wholly owned subsidiary of UTEK, in a stock transaction.

The acquisition includes the license to a DNA-based influenza vaccine developed at the University of Massachusetts Medical School in Worcester, Mass., according to a company news release.

CytoDyn is a Santa Fe, N.M., biopharmaceutical company.

UTEK is a specialty finance company focused on technology transfer.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.